Attached files

file filename
EX-99.1 - EX-99.1 - BIONOVO INCv222049_ex99-1.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 
May 11, 2011
 
 
Date of Report (Date of earliest event reported)
 
     
 
BIONOVO, INC.
 
 
(Exact Name of Registrant as Specified in Charter)
 

Delaware
 
001-33498
 
20-5526892
(State or Other
 
(Commission File Number)
 
(IRS Employer
Jurisdiction of Incorporation)
     
Identification No.)
 
 
5858 Horton Street, Suite 400, Emeryville, CA 94608
 
 
(Address of Principal Executive Offices)  (Zip Code)
 
     
 
(510) 601-2000
 
 
(Registrant's telephone number, including area code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 2.02.            Results of Operations and Financial Condition.
 
On May 11, 2011, Bionovo, Inc. (the “Company”) announced via press release the Company’s financial results for its first quarter ended March 31, 2011. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
 
The information in the report, including Exhibit 99.1 attached hereto as it relates to the Company’s Results of Operations and Financial Condition, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
 
Item 7.01.            Regulation FD Disclosure.
 
The information provided in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference in its entirety.
 
Item 9.01.            Financial Statements and Exhibits.
 
(d)         Exhibits.
 
Exhibit
   
Number
   
     
99.1
  
Press release from Bionovo, Inc., dated May 11, 2011, titled “Bionovo Announces First Quarter 2011 Highlights and Financial Results.”
 
 
1

 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Bionovo, Inc.
     
Date:  May 11, 2011
By:
/s/ Isaac Cohen
   
Isaac Cohen
   
Chairman and Chief Executive Officer

 
2

 

EXHIBIT INDEX

99.1
Press release from Bionovo, Inc., dated May 11, 2011, titled “Bionovo Announces First Quarter 2011 Highlights and Financial Results.”